BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma. Issue 8 (4th April 2020)

• Record Type: Journal Article
• Authors: Shi, Chengzhang; Ye, Zhao; Han, Jie; Ye, Xiaoqing; Lu, Wenchao; Ji, Chenxing; Li, Zizhou; Ma, Zengyi; Zhang, Qilin; Zhang, Yichao; He, Wenqiang; Chen, Zhengyuan; Cao, Xiaoyun; Shou, Xuefei; Zhou, Xiang; Wang, Yongfei; Zhang, Zhaoyun; Li, Yiming; Ye, Hongying; He, Min; Chen, Hong; Cheng, Haixia; Sun, Jun; Cai, Jianyong; Huang, Chuanxin; Ye, Fei; Luo, Cheng; Zhou, Bing; Ding, Hong; Zhao, Yao
• Is Part Of: Neuro-oncology. Volume 22:Issue 8(2020)
• Page Start: 1114
• Page End: 1125
• Publication Date: 2020-04-04
• Subjects: BRD4 -- GHPA -- NFPA -- target -- ZBC-260; Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noaa084
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: Background: Nonfunctioning pituitary adenoma (NFPA) and growth hormone pituitary adenoma (GHPA) are major subtypes of pituitary adenomas (PAs). The primary treatment is surgical resection. However, radical excision remains challenging, and few effective medical therapies are available. It is urgent to find novel targets for the treatment. Bromodomain-containing protein 4 (BRD4) is an epigenetic regulator that leads to aberrant transcriptional activation of oncogenes. Herein, we investigated the pathological role of BRD4 and evaluated the effectiveness of BRD4 inhibitors in the treatment of NFPA and GHPA. Methods: The expression of BRD4 was detected in NFPA, GHPA, and normal pituitary tissues. The efficacies of BRD4 inhibitors were evaluated in GH3 and MMQ cell lines, patient-derived tumor cells, and in vivo mouse xenograft models of PA. Standard western blots, real-time PCR, and flow cytometry experiments were performed to investigate the effect of BRD4 inhibitors on cell cycle progression, apoptosis, and the expression patterns of downstream genes. Results: Immunohistochemistry studies demonstrated the overexpression of BRD4 in NFPA and GHPA. In vitro and in vivo studies showed that treatment with the BRD4 inhibitor ZBC-260 significantly inhibited the proliferation of PA cells. Further mechanistic studies revealed that ZBC-260 could downregulate the expression of c-Myc, B-cell lymphoma 2 ( Bcl2 ), and related genes, which are vital factors in pituitary tumorigenesis. Conclusion: In this study, we determined the overexpression of BRD4 in NFPA and GHPA and assessed the effects of BRD4 inhibitors on PA cells in vitro and in vivo. Our findings suggest that BRD4 is a promising therapeutic target for NFPA and GHPA.